Cargando cotizaciones...
Previsión
| Comprar |
2 |
| Mantener |
2 |
| Vender |
1 |
Noticias Ir al feed de noticias
Organigram integrates Sanity Group and names new management
Organigram integrates the Sanity Group and appoints Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer; Tim Emberg remains President Canada. The acquisition's earn‑out clause was converted into a fixed earn‑out (85% of the original maximum): €20m in cash and about €76m in Organigram shares, payable no later than May 1, 2027; the number of shares is based on the 20‑day VWAP with a minimum price of C$3 and a maximum of C$4. Sanity most recently contributed about CAD 40m to Organigram's quarterly revenue (more than 35%); Sanity's quarterly revenue increased 34% to CAD 25.5m. The combined distribution network is expected to span Canada, Germany, Switzerland, Poland, the Czech Republic, the UK and Australia. » Más en de.investing.com
OrganiGram achieves record revenue and significantly higher adjusted EBITDA in Q3 2026
OrganiGram reported net revenue of CAD 105.8m in the third fiscal quarter (+49% year-on-year) and adjusted EBITDA of CAD 13.4m (+136%). A key driver was the first-time near-full consolidation of the Sanity Group, which has contributed about CAD 40m since acquisition and lifted international revenue to roughly 35%. Adjusted gross margin improved to 37% and management expects revenue above CAD 350m for 2026, but still sees negative free cash flow for the full year due to working capital needs. The stock rose about 4.4% premarket to USD 1.43, while liquidity and integration costs remain risk factors. » Más en de.investing.com
Organigram Global to release quarterly results for period ended June 30, 2026, on August 11, 2026
Organigram Global will publish results for the quarter ended June 30, 2026, on August 11, 2026. A consensus of four analysts expects EPS of -0.010 CAD per share versus -0.050 CAD a year ago. Five analysts forecast revenue to rise 36.8% to 96.9 million CAD and, for the current fiscal year, an average EPS of 0.120 CAD and annual revenue of 336.2 million CAD. » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 65,24M | 47,79% |
| Beneficio bruto | 25,55M | 56,69% |
| Beneficio neto | 65,09M | 1.758,40% |
| EBITDA | 9,95M | 494,37% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 153,48M€ |
Número de acciones | 140,78M |
Máximo/mínimo de 52 semanas | 1,92€ - 0,73€ |
| Dividendos | No |
Beta | 1,85 |
Ratio P/E | 2,75 |
Ratio PEG | 0,00 |
Ratio P/B | 0,49 |
Ratio P/S | 0,78 |
Perfil de la empresa
Organigram Holdings Inc. produziert und verkauft über seine Tochtergesellschaften Cannabis und aus Cannabis gewonnene Produkte in Kanada. Das Unternehmen bietet medizinische Cannabisprodukte, einschließlich Cannabisblüten, Cannabisöle und Verdampfer für zivile Patienten und Veteranen, Cannabis für den Freizeitgebrauch für Erwachsene unter den Marken Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds und Monjour sowie Cannabis-Esswaren und Konzentrate an. Das Unternehmen ist auch im Großhandelsversand von Cannabispflanzenstecklingen, getrockneten Blüten, Mischungen, Pre-Rolls und Produkten auf Cannabisderivatbasis an Einzelhändler und Großhändler für Cannabis für den Freizeitgebrauch für Erwachsene tätig. Das Unternehmen vertreibt seine Produkte sowohl online als auch telefonisch. Organigram Holdings Inc. wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Moncton, Kanada.
| Nombre | OrganiGram |
| CEO | James Yamanaka |
| Sede | Toronto,
on Canadá |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 21/05/2019 |
| Empleados | 1.139 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Frankfurt | 0OG.F |
NASDAQ | OGI |
Düsseldorf | 0OG.DU |
München | 0OG.MU |
Descubrir activos
Los accionistas de OrganiGram también invierten en los siguientes activos

